US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Vertex Pharmaceuticals (NQ:VRTX)

504.73 -2.01 (-0.40%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
77 78 Next >
News headline image
Vertex Pharmaceuticals (VRTX): The Evolution of a Biotech Powerhouse in 2026
As of March 20, 2026, Vertex Pharmaceuticals (NASDAQ: VRTX) has officially transcended its long-held identity as "the cystic fibrosis (CF) company." For over a decade, the Boston-based biotech giant... 
Via Finterra
Topics Intellectual Property
News headline image
Is CRISPR Therapeutics Stock a Buy Now? ↗
We will know even more about the company's prospects in a year as it releases clinical data for various pipeline candidates. 
Via The Motley Fool
News headline image
My Top 3 Drug Stocks for March 2026 ↗
These companies have impressive track records of navigating the biggest challenges in their industry. 
Via The Motley Fool
Topics Intellectual Property
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Merges Strong Fundamentals with Bullish Technical Setup ↗
Via Chartmill
Curious about which S&P500 stocks are generating unusual volume on Tuesday? Find out below. ↗
Via Chartmill
News headline image
Best Growth Stock to Buy Right Now: Eli Lilly vs. Vertex Pharmaceuticals ↗
Both have plenty to offer investors, but one has a better outlook. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Q4 Earnings Outperformers: Vertex Pharmaceuticals (NASDAQ:VRTX) And The Rest Of The Therapeutics Stocks
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASD... 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Momentum Stock to Research Further and 2 We Ignore
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorab... 
Via StockStory
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Shows High Technical and Setup Ratings for Potential Breakout ↗
Via Chartmill
News headline image
Is Vertex Pharmaceuticals Heading to $600? ↗
A new product approval may be right around the corner. 
Via The Motley Fool
News headline image
This Stock Just Jumped By 8%: Is It Too Late to Buy? ↗
The drugmaker is getting its mojo back. 
Via The Motley Fool
News headline image
2 Reasons to Watch VRTX and 1 to Stay Cautious
Vertex Pharmaceuticals’s 22.2% return over the past six months has outpaced the S&P 500 by 19.8%, and its stock price has climbed to $480.31 per share. This ... 
Via StockStory
Topics Stocks
News headline image
Vertex Pharmaceuticals Surges 8.3% as Renal Breakthrough Sparks Market Rally
In a significant milestone for precision medicine, Vertex Pharmaceuticals (NASDAQ:VRTX) emerged as the top performer in the S&P 500 on March 11, 2026, with its shares climbing 8.3%. The rally followed... 
Via MarketMinute
Topics Stocks
News headline image
Stocks making big moves yesterday: nLIGHT, Myriad Genetics, Vertex Pharmaceuticals, Nextpower, and Teladoc
Check out the companies making headlines yesterday: nLIGHT (NASDAQ:LASR): Laser company nLIGHT (NASDAQ:LASR) rose by 5.5% on Tuesday after the market reacted... 
Via StockStory
Topics Artificial Intelligence
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
News headline image
Why Vertex Pharmaceuticals (VRTX) Stock Is Up Today
What Happened? Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) jumped 8.3% in the afternoon session after the company announced positive resul... 
Via StockStory
Topics Economy
News headline image
The Great Biotech Divide: Vertex Soars on Multi-Franchise Breakthroughs as Novo Nordisk Stumbles in the Weight-Loss War
The healthcare sector has entered a period of sharp divergence in early 2026, creating a "bifurcated market" where clinical innovation is rewarding a select few while punishing former industry... 
Via MarketMinute
News headline image
Vertex Pharmaceuticals Surges as Breakthrough Kidney Data Sets New Gold Standard for IgA Nephropathy
Shares of Vertex Pharmaceuticals (Nasdaq: VRTX) climbed more than 8% today, reaching a record high as the biotechnology giant unveiled spectacular interim results from its pivotal Phase 3 RAINIER... 
Via MarketMinute
Which S&P500 stocks are moving on Tuesday? ↗
Via Chartmill
Top S&P500 movers in Tuesday's pre-market session ↗
Via Chartmill
News headline image
Nasdaq, S&P 500 Futures Turn Green On Iran War De-Escalation Signals: Why NVDA, ORCL, JOBY, VRTX, ZVRA Are On Traders' Radar Today ↗
Data from Stocktwits indicated that retail sentiment on SPY and QQQ was stabilizing. 
Via Stocktwits
Topics Artificial Intelligence ETFs Government
News headline image
VRTX Soars In Extended Hours After Experimental Drug Shows Positive Changes In Autoimmune Kidney Disease ↗
The company said that patients treated with povetacicept achieved a 52.0% reduction from baseline in urine protein to creatinine ratio at week 36, meeting the study’s key goal. 
Via Stocktwits
News headline image
Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Buying This 1 Biotech Stock Now Could Help Make You a Multimillionaire Retiree ↗
The company has performed well over the long run. 
Via The Motley Fool
Topics Intellectual Property Retirement
News headline image
Vertex to Participate in Upcoming March Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
2 Biotech Giants to Buy in 2026 ↗
Both of these players are leaders in their fields. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Forget CRISPR Therapeutics: This Gene‑Editing Player Already Boasts the Profits It Dreams Of ↗
These two biotechs have a lot in common. Their differences are even more pronounced. 
Via The Motley Fool
News headline image
Is CRISPR Therapeutics Stock Too Risky to Buy Right Now? ↗
CRISPR isn't profitable, but it does have an approved gene therapy treatment with loads of potential. 
Via The Motley Fool
News headline image
2 Top Healthcare Stocks to Buy in February ↗
Patience should pay off with these two healthcare giants. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
77 78 Next >